Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Annals of Hematology|March 28, 2021
The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter studySalvatore Leotta, Uros Markovic, Maria Cristina Pirosa, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|August 22, 2022
Role of computed tomography in transcatheter replacement of 'other valves': a comprehensive review of preprocedural imagingLuca Pugliese, Francesca Ricci, Alessandra Luciano, et al.
Blood Advances|October 25, 2024
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OSThomas Cluzeau, Fabio Guolo, Edmond Chiche, et al.
Blood Cancer Journal|October 7, 2020
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use programFabio Guolo, Luana Fianchi, Paola Minetto, et al.
Blood|February 26, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Sabina Chiaretti, Irene Della Starza, et al.
Annals of Hematology|August 26, 2025
Pegaspargase administration and tolerability in patients aged 55 years or older with acute lymphoblastic leukemia treated with the LAL1913 program. A subanalysis of the Campus ALL groupDavide Lazzarotto, Anna Maria Testi, Matteo Fanin, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Haematologica|January 15, 2026
Real-life management of 476 older adults with Philadelphianegative acute lymphoblastic leukemia: a Campus ALL studyMarco Cerrano, Davide Lazzarotto, Eleonora Boscaro, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
American Journal of Hematology|September 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell TransplantationFabio Guolo, Luana Fianchi, Maria Paola Martelli, et al.
Pageof 6